A microbiome-informed platform for the development and testing of bacterial therapies for colorectal cancer
用于开发和测试结直肠癌细菌疗法的微生物组信息平台
基本信息
- 批准号:9974305
- 负责人:
- 金额:$ 59.3万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-05-18 至 2024-04-30
- 项目状态:已结题
- 来源:
- 关键词:AcousticsAddressAmericanAnimal ModelAnimal TestingAnimalsAntibioticsApoptoticB lymphoid malignancyBacteriaBiologicalBiological AssayCRISPR/Cas technologyCancer EtiologyCancer ModelCancer cell lineCellsCessation of lifeClinical TrialsCloningCoculture TechniquesColonoscopyColorectalColorectal CancerColorectal NeoplasmsConsumptionCytolysisDataDevelopmentDiseaseEngineeringEnvironmentEnzymesEscherichia coliEvaluationFingerprintGeneticGenetic EngineeringGrowthHome environmentHumanHuman MicrobiomeHuman bodyImmune responseIn SituIn Situ HybridizationIn VitroLeadLibrariesLiquid substanceLocationMalignant NeoplasmsMammalian CellMetastatic Neoplasm to the LiverMicrofluidicsModelingModificationMolecularMucous MembraneMusNatural ProductsNatureOralOrganismOrganoidsPathogenicityPathologicPeptidesPlantsPopulationPopulation DensityPre-Clinical ModelPrevalenceProbioticsPropertyResearchSamplingSeriesSocietiesSolidSolid NeoplasmSystemTestingTherapeuticTherapeutic AgentsTherapeutic UsesTimeTissue SampleTissuesToxinTreatment EfficacyTumor BurdenTumor TissueWorkbasebeneficial microorganismcancer cellcancer therapycancer typechemotherapychimeric antigen receptor T cellscolorectal cancer treatmentcostcost effectiveeffective therapyefficacy testingexperimental studygenetically modified cellshuman diseasehuman tissuein vitro Assayin vivoin vivo imagingmicrobiomemicrofluidic technologymouse modelnovelpeptide drugpre-clinicalprospectivesynthetic biologytherapeutic candidatetherapeutic enzymetherapeutic evaluationtherapeutic proteintherapy developmenttooltumortumor microbiometumor specificity
项目摘要
Project Summary
There is a clear imperative to develop potent, cost effective therapeutics to confront the
challenge cancer poses to society. Here we address this need by developing synthetically
engineered cells effective against a broad range of cancer types with a special emphasis on
colorectal cancer (CRC). This cancer type is the second most common cause of cancer death
in the US, with more than 50,000 Americans dying every year. Recent research demonstrates
the power of genetic engineering to make significant advances towards more efficacious cancer
therapy. The introduction of genetically engineered cells, such as chimeric antigen receptor T
(CAR T) cells, has shown great promise for treating many types of B cell malignancies, but
unfortunately targeting CAR T cells to solid tumors remains challenging. In this project we will
use the tools of synthetic biology to make new engineered therapies based on bacterial rather
than mammalian cells. Certain bacterial species have demonstrated a useful ability to “home in”
and selectively colonize solid tumors without infecting healthy tissue. This tumor targeting
property will be exploited in the proposed work to deliver safe, effective therapies directly to the
locations where they are needed most: the solid core of tumors. Previously we developed a
bacterial therapeutic and tested it in an animal model of metastatic disease. In contrast to other
approaches utilizing bacterial cells, this “lysis strain” does not require specialized genetic
modifications for the secretion of encoded cargo, it simply releases it into the environment when
the cells burst. Initially we will genetically modify the lysis strain to produce a wide range of
therapeutics for testing, including toxins (from bacteria, animals and plants), enzymes,
antibiotics, and apoptotic peptides. Next we will analyze the tumor microbiome from human
samples since we hypothesize that the native bacterial population's composition will provide a
unique signature (analogous to a fingerprint) that can be used to divide tumors into distinct
subtypes. We expect to use these fingerprints to identify other species with superior suitability
for therapeutic delivery in treating CRC. Once identified we will develop two in vitro assays for
testing the candidate strains. We will use microfluidic technology to create a high throughput
co-culturing system for bacteria and a cancer cell line. In parallel, we will develop a co-culturing
system for bacteria and organoids that are generated from the same human tumor samples
which had been previously used for strain identification and fingerprinting. Lastly we will test the
most promising therapies in an animal model of colorectal cancer to determine efficacy in a pre-
clinical model.
项目摘要
显然有必要开发有效且具有成本效益的治疗方法来应对这种情况
癌症给社会带来的挑战在这里,我们通过综合开发来满足这一需求。
工程细胞对广泛的癌症类型有效,特别强调
结直肠癌(CRC)。这种癌症类型是癌症死亡的第二大常见原因
在美国,每年有超过5万美国人死亡。最近的研究表明,
基因工程的力量,使更有效的癌症的重大进展,
疗法基因工程细胞的引入,如嵌合抗原受体T
(CAR T)细胞,已经显示出治疗许多类型的B细胞恶性肿瘤的巨大前景,但是
不幸的是,将CAR T细胞靶向实体瘤仍然具有挑战性。在这个项目中,我们将
利用合成生物学的工具,
而不是哺乳动物细胞。某些细菌物种已经证明了一种有用的“归巢”能力。
并且选择性地定殖实体肿瘤而不感染健康组织。这种肿瘤靶向
财产将被利用在拟议的工作,提供安全,有效的治疗直接向
最需要它们的位置:肿瘤的实核。以前我们开发了一个
细菌治疗,并在转移性疾病的动物模型中进行了测试。相对于其他
利用细菌细胞的方法,这种“裂解菌株”不需要专门的遗传学。
当编码货物的分泌发生改变时,它只是将其释放到环境中,
细胞就会破裂最初,我们将对裂解菌株进行遗传修饰,以产生广泛的
用于测试的治疗剂,包括毒素(来自细菌、动物和植物),酶,
抗生素和凋亡肽。接下来,我们将分析来自人类的肿瘤微生物组。
因为我们假设天然细菌种群的组成将提供一个
独特的签名(类似于指纹),可用于将肿瘤分为不同的
亚型我们期望利用这些指纹来鉴定其他具有上级适应性的物种
用于治疗CRC的治疗性递送。一旦确定,我们将开发两种体外试验,
测试候选菌株。我们将使用微流控技术来创造一个高通量的
用于细菌和癌细胞系的共培养系统。与此同时,我们将开发一种共同培养
用于从相同的人类肿瘤样品产生的细菌和类器官的系统
其先前用于菌株鉴定和指纹分析。最后,我们将测试
最有希望的治疗方法,以确定在结肠直肠癌的动物模型中的疗效,
临床模型
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
JEFF M HASTY其他文献
JEFF M HASTY的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('JEFF M HASTY', 18)}}的其他基金
Development of Engineered Native Bacteria as a Tool for Functional Manipulation of the Gut Microbiome
开发工程原生细菌作为肠道微生物组功能操纵的工具
- 批准号:
10737475 - 财政年份:2023
- 资助金额:
$ 59.3万 - 项目类别:
Reprogramming cell-fate decisions through predictive modeling and synthetic biology
通过预测模型和合成生物学重新编程细胞命运决定
- 批准号:
10784558 - 财政年份:2022
- 资助金额:
$ 59.3万 - 项目类别:
Reprogramming cell-fate decisions through predictive modeling and synthetic biology
通过预测模型和合成生物学重新编程细胞命运决定
- 批准号:
10344041 - 财政年份:2022
- 资助金额:
$ 59.3万 - 项目类别:
Reprogramming cell-fate decisions through predictive modeling and synthetic biology
通过预测模型和合成生物学重新编程细胞命运决定
- 批准号:
10706965 - 财政年份:2022
- 资助金额:
$ 59.3万 - 项目类别:
Reprogramming cell-fate decisions through predictive modeling and synthetic biology
通过预测模型和合成生物学重新编程细胞命运决定
- 批准号:
10908026 - 财政年份:2022
- 资助金额:
$ 59.3万 - 项目类别:
Design and characterization of bacterial population dynamics in solid tumor models
实体瘤模型中细菌种群动态的设计和表征
- 批准号:
10212134 - 财政年份:2021
- 资助金额:
$ 59.3万 - 项目类别:
Design and characterization of bacterial population dynamics in solid tumor models
实体瘤模型中细菌种群动态的设计和表征
- 批准号:
10456087 - 财政年份:2021
- 资助金额:
$ 59.3万 - 项目类别:
A microbiome-informed platform for the development and testing of bacterial therapies for colorectal cancer
用于开发和测试结直肠癌细菌疗法的微生物组信息平台
- 批准号:
10166805 - 财政年份:2020
- 资助金额:
$ 59.3万 - 项目类别:
A microbiome-informed platform for the development and testing of bacterial therapies for colorectal cancer
用于开发和测试结直肠癌细菌疗法的微生物组信息平台
- 批准号:
10397153 - 财政年份:2020
- 资助金额:
$ 59.3万 - 项目类别:
A microbiome-informed platform for the development and testing of bacterial therapies for colorectal cancer
用于开发和测试结直肠癌细菌疗法的微生物组信息平台
- 批准号:
10631898 - 财政年份:2020
- 资助金额:
$ 59.3万 - 项目类别:
相似海外基金
African American (AA) Communities Speak: Partnering with AAs in the North and South to Train Palliative Care Clinicians to Address Interpersonal and Systemic Racism and Provide Culturally Aligned Care
非裔美国人 (AA) 社区发言:与北部和南部的 AA 合作,培训姑息治疗临床医生,以解决人际和系统性种族主义并提供文化一致的护理
- 批准号:
10734272 - 财政年份:2023
- 资助金额:
$ 59.3万 - 项目类别:
GODDESS (Gathering Online for Dialogue and Discussion to Enhance Social Support): Engaging young African American women in a virtual group app to address alcohol misuse, sexual risk, and PrEP in NC
GODDESS(在线聚集进行对话和讨论,以加强社会支持):让年轻的非裔美国女性参与虚拟团体应用程序,以解决北卡罗来纳州的酒精滥用、性风险和 PrEP 问题
- 批准号:
10541028 - 财政年份:2022
- 资助金额:
$ 59.3万 - 项目类别:
GODDESS (Gathering Online for Dialogue and Discussion to Enhance Social Support): Engaging young African American women in a virtual group app to address alcohol misuse, sexual risk, and PrEP in NC
GODDESS(在线聚集进行对话和讨论,以加强社会支持):让年轻的非裔美国女性参与虚拟团体应用程序,以解决北卡罗来纳州的酒精滥用、性风险和 PrEP 问题
- 批准号:
10684239 - 财政年份:2022
- 资助金额:
$ 59.3万 - 项目类别:
A multidimensional Digital Approach to Address Vaccine Hesitancy and Increase COVID-19 Vaccine Uptake among African American Young Adults in the South
解决疫苗犹豫问题并提高南方非裔美国年轻人对 COVID-19 疫苗接种率的多维数字方法
- 批准号:
10395616 - 财政年份:2021
- 资助金额:
$ 59.3万 - 项目类别:
A multidimensional Digital Approach to Address Vaccine Hesitancy and Increase COVID-19 Vaccine Uptake among African American Young Adults in the South
解决疫苗犹豫问题并提高南方非裔美国年轻人对 COVID-19 疫苗接种率的多维数字方法
- 批准号:
10786490 - 财政年份:2021
- 资助金额:
$ 59.3万 - 项目类别:
Reducing Hypertension among African American Men: A Mobile Stress Management Intervention to Address Health Disparities
减少非裔美国男性的高血压:解决健康差异的移动压力管理干预措施
- 批准号:
10821849 - 财政年份:2021
- 资助金额:
$ 59.3万 - 项目类别:
Reducing Hypertension among African American Men: A Mobile Stress Management Intervention to Address Health Disparities
减少非裔美国男性的高血压:解决健康差异的移动压力管理干预措施
- 批准号:
10384110 - 财政年份:2021
- 资助金额:
$ 59.3万 - 项目类别:
A multidimensional Digital Approach to Address Vaccine Hesitancy and Increase COVID-19 Vaccine Uptake among African American Young Adults in the South
解决疫苗犹豫问题并提高南方非裔美国年轻人对 COVID-19 疫苗接种率的多维数字方法
- 批准号:
10336591 - 财政年份:2021
- 资助金额:
$ 59.3万 - 项目类别:
Community-Academic Partnerships to Address COVID-19 Inequities within African American Communities
社区学术伙伴关系解决非裔美国人社区内的 COVID-19 不平等问题
- 批准号:
10245326 - 财政年份:2021
- 资助金额:
$ 59.3万 - 项目类别:
Engaging scientists and communities to address the impacts of substance abuse on American Indian and Alaska Native children and families: The Native Children's Research Exchange Annual Meetings
让科学家和社区参与解决药物滥用对美洲印第安人和阿拉斯加原住民儿童和家庭的影响:原住民儿童研究交流年会
- 批准号:
10657317 - 财政年份:2020
- 资助金额:
$ 59.3万 - 项目类别: